MedTrace Logo

Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

NCT05895877 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2023-06-09

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of Goofice® in patients with chronic constipation.

Conditions

Interventions

DRUG

Goofice®

Once daily before breakfast.

DRUG

Goofice® Placebo

Once daily before breakfast.

Sponsors & Collaborators

  • Synmosa Biopharma Corp.

    lead INDUSTRY

Principal Investigators

  • Ming-Shiang Wu · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-21
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05895877 on ClinicalTrials.gov